Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease
Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744
 CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI
 1744 CL. Olodaterol dose 40 mcg was investigated only in the open-label extension part for
 additional PK assessments which are not defined as primary or secondary endpoints.
Inclusion criteria:

 1. Diagnosis of chronic obstructive pulmonary disease

 2. Smoking history of more than 10-pack years

 Exclusion criteria:

 1. History of asthma, allergic rhinitis, myocardial infarction or unstable of
 life-threatening cardiac arrhythmias

 2. Marked baseline prolongation of QT/QTc interval